Selank: Anxiolytic Nootropic Heptapeptide for Stress Resilience and Calm Focus
This article is informational in nature. Selank is an unapproved substance in Western jurisdictions and is restricted to research purposes.
1. Baseline Profile and Tuftsin Origin
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). Tuftsin is naturally produced by enzymatic cleavage of the IgG heavy chain in the spleen, stimulating phagocytosis.
To overcome tuftsin's extreme metabolic instability in plasma, developers added a Pro-Gly-Pro C-terminal sequence. This modification provides steric hindrance against exopeptidases, extending its half-life and shifting its physiological activity from immunomodulation to central nervous system neurotransmitter regulation, supporting Cognitive & Neuro health.
2. Allosteric Modulation of GABAergic Neurotransmission
Selank's primary anxiolytic mechanism is positive allosteric modulation (PAM) of the GABA-A receptor. It binds to a distinct regulatory site, increasing the receptor's affinity for endogenous GABA, which increases chloride channel opening frequency and hyperpolarizes the neuron, dampening excitation.
Because it relies on endogenous GABA, its inhibitory effect is physiologically capped, avoiding the respiratory depression risks of direct agonists.Frontal cortex transcriptomic analysis in mice showed Selank (300 mcg/kg) alters the expression of 84 neurotransmission-related genes. Within 1 hour, 45 genes showed significant expression changes, and 22 genes maintained this profile at 3 hours.
3. Upregulation of Brain-Derived Neurotrophic Factor
Selank promotes hippocampal neuroplasticity by upregulating BDNF gene expression. BDNF binds to TrkB receptors, activating the PI3K/Akt and MAPK/ERK cascades that regulate dendritic arborization and long-term potentiation (LTP).
In rodent models of chronic alcohol intoxication (which degrades BDNF, causing memory impairment), Selank administration completely prevented ethanol-induced BDNF depletion in the hippocampus and prefrontal cortex. This neurotrophic regulation protects hippocampal networks from cortisol-induced glucocorticoid toxicity during acute stress, setting Selank apart from sedative anxiolytics.
4. Enkephalinase Inhibition and Opioid Preservation
Selank modulates the endogenous opioid system by competitively inhibiting enkephalin-degrading enzymes. Psychological stress accelerates enkephalin turnover, depleting anxiolytic reserves and precipitating neurasthenia. Selank competitive inhibits dipeptidyl peptidase-IV (DPP-IV) and other aminopeptidases.
It exhibits an IC50 of 15 μM for enkephalinase inhibition, significantly outperforming classical peptidase inhibitors like puromycin (IC50 = 10 mM). Preserving enkephalin half-lives in the synaptic cleft buffers stress responses, mitigating panic and phobic symptoms. This effect requires the full heptapeptide sequence.
5. Immunomodulatory Pathways and Cytokine Expression
Inheriting tuftsin's immunomodulatory properties, Selank helps correct stress-induced immune dysregulation. Chronic anxiety and depression are neuroinflammatory states characterized by Th1/Th2 cytokine imbalances. In vitro assays using blood cells from depressed patients showed Selank (10^-7 M) completely suppressed pathological IL-6 expression.
In vivo models of social stress confirmed Selank reduces elevated IL-1beta, IL-6, and TNF-alpha to normal levels. Clinical trials in patients with generalized anxiety disorder (GAD) showed Th1/Th2 cytokine balancing correlated directly with the reduction of anxiety symptoms, eliminating cytokine-induced sickness behavior.
6. Clinical Efficacy
A comparative clinical trial in 62 patients with GAD and neurasthenia compared Selank directly to medazepam (a benzodiazepine). Anxiolytic efficacy was statistically indistinguishable, but medazepam induced sedation, motor ataxia, and cognitive slowing. In contrast, Selank produced anti-asthenic effects, improving mental clarity and cognitive endurance.
Selank also restored depleted tau(1/2) leu-enkephalin serum levels, which correlated with anxiety reduction. In another study, combining Selank with phenazepam accelerated clinical improvement on the Hamilton Depression Rating Scale (HDRS) compared to phenazepam monotherapy. Selank also attenuated withdrawal parameters in morphine-dependent rodents.
7. Intranasal Pharmacokinetics and Nose-to-Brain Transport
Oral administration is ineffective due to gastrointestinal proteolysis. Intranasal delivery is the optimal route, allowing nose-to-brain (N2B) transport along olfactory and trigeminal nerve pathways. This bypasses the blood-brain barrier, which excludes 100% of large biopharmaceuticals.
Peak therapeutic concentrations in the CSF are achieved in minutes. Although Selank has a short plasma half-life of 2 minutes, its concentration in brain parenchyma remains highly stable and declines slowly. This pharmacokinetic stability supports standard dosing schedules (100-600 mcg, 1-3x daily) for sustained cognitive baseline support.
8. Dosing, Synergistic Stacking, and Safety
Standard intranasal doses range from 100 to 600 mcg daily. Selank exhibits no observable LD50, does not induce respiratory depression, and has no hepatotoxicity or nephrotoxicity, as it degrades into inert amino acids. It does not cause receptor desensitization, tolerance, or withdrawal upon cessation.
Synergistic Stacks: Selank is commonly stacked with Semax and Cortexin. While Semax upregulates dopaminergic tone and executive drive, it can trigger mild anxiety. Selank is co-administered to blunt autonomic hyperarousal, yielding a state of "calm focus." Cortexin supports this stack by providing structural neuropeptide substrates for metabolic repair.